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Background
As recently reported, HIV-1 candidate vaccines (DNA-C;
NYVAC-C) expressing an artificial polyprotein consisting
of Gag, Pol and Nef (GPN) as well as a secreted from of
gp120 (E) induced high levels of polyfunctional, HIV-spe-
cific CD4+ and CD8+ T-cells in phase I clinical trials
(EUROVACC). Thereby, T cell responses showed some
dominance of Env over Gag/Pol reponses.
Methods
To improve Gag/Pol specific immunogenicity, some mod-
ifications were included comprising (i) re-introduction of
the natural gag-pol frameshift allowing budding and
release of GPN particles from transduced cells, (ii) inacti-
vation the protease and (iii) separation of Gag (+G) and
PolNef (PN) on two plasmids. Following various proto-
cols, different combinations of GPN derivatives, G, PN
and Env encoding plasmids were administered i.m. into
Balb/c mice to overcome competition for presentation of
relevant epitopes.
Results
Budding competence increased levels of Gag specific, IFNγ
producing T cells. The injection of equimolar amounts of
G and PN increased Pol specific responses, whereas Gag
responses remained on a constant level.
Co-administering Env in a mixture with GPN derivatives
or G largely abrogated Gag-specific responses and resulted
in the induction of almost exclusively Env specific T-cells,
whereas injection of Env and GPN in separate muscles as
well as a timely separated administration induced Gag,
Pol and Env specific T-cells at substantial levels.
Conclusion
In sum, the modifications increased Gag and Pol specific
T-cell responses up to 10-fold if compared to the GPN
immunogens as used in the clinical trial. Such DNA vac-
cines may represent valuable priming immunogens for
subsequent booster immunisations using second genera-
tion poxviral vectors to deliver optimised immunogens.
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